The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $16,468,078 in first-year total cost, median $2,839,293.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-G (52)]1
- Special Emphasis Panel[ZNS1 SRB-G (58)]1
- Special Emphasis Panel[ZNS1 SRB-G (62)]1
- Special Emphasis Panel[ZNS1 SRB-G (65)]1
Most frequent institutions
- CINCINNATI CHILDRENS HOSP MED CTR1
- UNIVERSITY OF MINNESOTA1
- UNIVERSITY OF TEXAS MED BR GALVESTON1
- UNIVERSITY OF VIRGINIA1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Ketamine Add-On for Established Status Epilepticus Treatment Trial (KESETT)1UG3NS131532-01A1 | CHAMBERLAIN, JAMESKAPUR, JAIDEEPROSENTHAL, ERIC S.SILBERGLEIT, ROBERT | UNIVERSITY OF VIRGINIA, VA | $9,296,510 | ZNS1 |
| 2024 | A Phase 3 clinical trial of an e-health behavioral intervention to improve executive functioning in adolescents with epilepsy1UG3NS129558-01A1 | MODI, AVANI C | CINCINNATI CHILDRENS HOSP MED CTR, OH | $1,492,982 | ZNS1 |
| 2023 | Chronic Subdural Hematoma Treatment with Embolization vs Surgery or MedicalManagement Study (CHESS)1UG3NS128397-01A1 | CASSARLY, CHRISTYKAN, PETER TZE MANSIDDIQ, FARHANTHOMAS, AJITH | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $3,533,470 | ZNS1 |
| 2023 | Encochleated Oral Amphotericin for HIV-related Cryptococcal Meningitis Trial: Phase 3 Trial1UG3NS131096-01 | BOULWARE, DAVID RMEYA, DAVID BISAGAYA | UNIVERSITY OF MINNESOTA, MN | $2,145,116 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.